Free Trial

HEALTHCARE: GSK (A2/A): RSV Vaccine Setback

HEALTHCARE
  • The US CDC's Advisory Committee on Immunization Practices are restricting the target group for the RSV vaccine to older adults.
  • This is a set-back for GSK who had seen Arexvy as being a blockbuster with Peak Annual Sales of $3+bn.  
  • The total addressable market is now likely to be only 1/3 of that envisaged.
  • Not a credit mover per se but certainly a set-back for GSK & Pfizer.
  • Overall, Vaccines make up 1/3 of Glaxo's sales.

Link to FT Story

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.